sur MEDINCELL (EPA:MEDCL)
Medincell's Rising Revenue and Upcoming Submissions
On July 30, 2025, Medincell announced an upward revision of its 2025 revenue outlook for UZEDY®, a subcutaneous risperidone treatment for schizophrenia. The expected revenue is now projected between $190 million and $200 million, up from the previous forecast of approximately $160 million. UZEDY® has been commercialized in the U.S. since May 2023, with 2024 sales recorded at $117 million. The first half of 2025 saw sales increase to $93 million, a 2.3x rise from the same period in 2024.
Additionally, Medincell's Olanzapine Long-Acting Injectable is on track for a New Drug Application (NDA) submission in Q4 2025. The completion of its Phase 3 trial in January 2025 showed positive efficacy results. Upon approval, Medincell is poised to receive significant royalties and milestone payments.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MEDINCELL